Clinicaltrials.gov: Rep. Waxman Wants PhRMA To Describe Steps To Improve Compliance

Waxman takes issue with PhRMA’s failure to appear at a recent House hearing to discuss FDA’s clinical trial registry. He asks the association to submit documents it has sent to member companies regarding compliance with the submission requirement.